TiGenix

TiGenix NV/SA (TiGenix) and its subsidiaries TiGenix Inc. and TC CEF LLC are a Belgium-based biomedical company focused on innovative local treatments for damaged and osteoarthritic joints. The company is harnessing the power of regenerative medicine to develop long-lasting therapies for these indications, validated by controlled clinical studies. Located in Leuven, TiGenix is affiliated with the Catholic University of Leuven and Ghent University. TiGenix is developing a range of products targeting specific musculoskeletal issues. The primary indication among these is cartilage damage, a debilitating condition that severely affects patients' mobility and function.